Aperam


FY23 in line; some hopes for recovery (H2 24)?

12/02/24 -"The group released an expected set of results, while it also anticipates a rather similar Q1 24 vs Q3 23. Even if the market is still depressed, particularly in Europe, a stabilisation is welcome and ..."

Pages
70
Language
English
Published on
12/02/24
You may also be interested by these reports :
30/10/26
Q3 was exceptional for Boliden, with profit metrics >20% ahead of street expectations. This is impressive considering that Garpenberg operations ...

29/10/26
Q3, while traditionally focused on sales (which remained restrained), was mostly about surprise 2026 EBITDA guidance – which implies that the H1 ...

28/10/26
SSAB’s Q326 results were broadly in line, with revenues up 11.6% YoY to SEK25.6bn and EBIT up 15.4% to SEK2.2bn, slightly ahead of expectations. ...

23/10/26
Even though Norsk’s Q3 results were strong in aggregate – led by Primary Metal – they missed street expectations. Also, all other divisions faced ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO